Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymoglobulin versus basiliximab induction with tacrolimus-to-sirolimus conversion in DCD kidney transplant recipients
ACTRN12611001224910Phase 4Not yet recruiting
- Sponsor
- United States Department of Health and Human Services
- Start
- Apr 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of antithymocyte globulin, basiliximab, tacrolimus, sirolimus, mycophenolic acid in Kidney allograft status (RTx), sponsored by United States Department of Health and Human Services. Planned start Apr 2012; status: not yet recruiting.
02
Drugs
antithymocyte globulinbasiliximabtacrolimussirolimusmycophenolic acid
03
Conditions
Kidney allograft status (RTx)
Beyond the preview
Go deeper on ACTRN12611001224910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611001224910.